KALYDECO (ivacaftor)

Self-Administration - Oral

Indications for Prior Authorization:
  • Indicated for the treatment of cystic fibrosis (CF) in patients age 4 months and older who have one mutation in the CFTR gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data
    • If the patient's genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of a CFTR mutation followed by verification with bi-directional sequencing when recommended by the mutation test instructions for use.
Coverage Criteria:

For diagnosis of cystic fibrosis (CF):

  • Dose is appropriate for the patient’s age and weight OR does not exceed 150mg every 12 hours, AND
  • Patient is 4 months of age or older, AND
  • Patient has a diagnosis of cystic fibrosis (CF) as confirmed by chart note documentation, AND
  • Patient has at least one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data as detected by an FDA-cleared cystic fibrosis mutation test or a test performed at a Clinical Laboratory Improvement Amendments (CLIA)-approved facility, AND
  • Prescribed by or in consultation with a pulmonologist or a specialist affiliated with a CF care center, AND
  • Kalydeco is not prescribed concurrently with other CFTR modulators (e.g., Orkambi, Symdeko, Trikafta)
Reauthorization Criteria:

For diagnosis of cystic fibrosis (CF):

  • Dose is appropriate for the patient’s age and weight OR does not exceed 150mg every 12 hours, AND
  • Documentation of positive clinical response (i.e., improvement in lung function [percent predicted forced expiratory volume in one second {PPFEV1}], decreased number of pulmonary exacerbations) to therapy, AND
  • Prescribed by or in consultation with a pulmonologist or a specialist affiliated with a CF care center, AND
  • Kalydeco is not prescribed concurrently with other CFTR modulators (e.g., Orkambi, Symdeko, Trikafta)
Coverage Duration:
  • Initial: 1 year
  • Reauthorization: 1 year
Authorization is not covered for the following:

The use of this drug for indications not listed in this policy does not meet the coverage criteria established by the Western Health Advantage (WHA) Pharmacy and Therapeutics (P&T) Committee.

Additional Information:
  • Adults and pediatric patients ages 6 years and older: 150 mg every 12 hours
  • Patients ages 4 months to less than 6 years:

  

  • Patients aged 6 months and older with moderate hepatic impairment (Child-Pugh Class B): one tablet or one packet of oral granules once daily
  • Patients aged 6 months and older with severe hepatic impairment (Child-Pugh Class C): one tablet or one packet of oral granules once daily or less frequently
  • Not recommended in patients with hepatic impairment below 6 months of age
  • CFTR gene mutations responsive to Kalydeco are marked with an asterisk

  • Kalydeco should be taken with fat-containing food
  • Kalydeco is not recommended for use in children aged 4 months to less than 6 months with hepatic impairment and/or taking concomitant moderate or strong CYP3A inhibitors
  • Warnings for transaminase (ALT or AST) elevations, concomitant use with CYP3A inducers, cataracts
Policy Updates:
  • 10/19/21 – New policy approved by P&T.
References:
  • Kalydeco Prescribing Information. Vertex Pharmaceuticals Incorporated. Boston, MA. December 2020.
  • Ramsey BW, Davies J, McElvaney G, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med. 2011;365:1663-1672.

Last review date: October 19, 2021

Rite Aid Pharmacy Patients: All Rite Aid pharmacies nationwide are closing! Please be on the lookout for information from Rite Aid pharmacies about their bankruptcy and store closures. Call your Rite Aid pharmacy for questions about your prescriptions and new pharmacy options. WHA is here to help as well. Contact Us via Phone